Search Result
Results for "
CCL2
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
5
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0673
-
Pirfenidone
Maximum Cited Publications
80 Publications Verification
AMR69
|
TGF-beta/Smad
CCR
|
Inflammation/Immunology
Cancer
|
|
Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities [2] .
|
-
-
- HY-W007376
-
|
3-Formylindole
|
Endogenous Metabolite
|
Others
|
|
Indole-3-carboxaldehyde (3-Formylindole), a banlangen extract, is the product of the oxidative degradation of indole-3-acetic acid (IAA) by crude enzyme preparations from etiolated pea seedlings. Indole-3-carboxaldehyde is a biochemical used to prepare analogs of the indole phytoalexin cyclobrassinin. Indole-3-carboxaldehyde also enhances the epithelial barrier and anti-inflammatory activity in the intestinal tract [2].
|
-
-
- HY-B0498
-
|
AF2838
|
CCR
|
Neurological Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Bindarit (AF2838) is a selective inhibitor of the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8, and no effect on other CC and CXC chemokines such as MIP-1α/CCL3, MIP-1β/CCL4, MIP-3/CCL23. Bindarit also has anti-inflammatory activity .
|
-
-
- HY-120501
-
|
|
NF-κB
|
Inflammation/Immunology
|
|
B022 is a potent and selective NF-κB-inducing kinase (NIK) inhibitor (Ki of 4.2 nM; IC50=15.1 nM). B022 protects liver from toxin-induced inflammation, oxidative stress, and injury [2]. B022 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-B1322
-
-
-
- HY-B1203
-
|
9α-Fludrocortisone; 9α-Fluorcortisol
|
Mineralocorticoid Receptor
Glucocorticoid Receptor
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Fludrocortisone (9α-Fludrocortisone) is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency [2] .
|
-
-
- HY-B1322A
-
-
-
- HY-P99188
-
|
CNTO 888
|
CCR
|
Cancer
|
|
Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) monoclonal antibody. Carlumab binds and neutralises profibrotic activities of human CCL2. Carlumab inhibits tumor growth by reducing macrophage infiltration and decreasing tumor microvascular density. Carlumab can be used for the research of cancer, suah as prostate cancer [2].
|
-
-
- HY-P990297
-
|
|
CCR
HIV
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV [2] .
|
-
-
- HY-P99781
-
|
MLN-1202
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) [2] .
|
-
-
- HY-B1322B
-
-
-
- HY-B0673R
-
|
AMR69 (Standard)
|
Reference Standards
TGF-beta/Smad
CCR
|
Inflammation/Immunology
Cancer
|
|
Pirfenidone (Standard) is the analytical standard of Pirfenidone. This product is intended for research and analytical applications. Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities [2] .
|
-
-
- HY-B1076
-
|
HMS; 6α-Methyl-11β-hydroxyprogesterone
|
VEGFR
CCR
STAT
|
Neurological Disease
|
|
Medrysone (HMS; 6α-Methyl-11β-hydroxyprogesterone) is a STAT6 modulator and M2 macrophage polarization inducer. Medrysone enhances IL-4-triggered STAT6 activation, upregulates the expression of M2 markers, and promotes the secretion of VEGF and CCL2. Medrysone also enhances the pro-migratory activity of M2-like macrophages toward endothelial cells. By regulating macrophage polarization and related repair pathways, Medrysone significantly promotes corneal wound repair in a rat mechanical injury model. Medrysone can be used for research related to corneal injury .
|
-
-
- HY-B0673S1
-
|
LYT-100; AMR69-d3
|
Isotope-Labeled Compounds
|
Others
|
|
Deupirfenidone-d3 is the deuterium labeled Pirfenidone (HY-B0673). Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities [2] .
|
-
-
- HY-N0444
-
|
|
Reactive Oxygen Species (ROS)
|
Inflammation/Immunology
|
|
Rubiadin is an orally active polyketide-derived compound and free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections [2] .
|
-
-
- HY-148100
-
|
NOX-E36
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Emapticap pegol (NOX-E36) is a inhibitor of pro-inflammatory chemokine C-C motif-ligand 2 (CCL2). Emapticap pegol is a 40-nucleotide oligonucleotide aptamer, displays different Spiegelmers (L-RNA aptamer) isform in human (NOX-E36) and mouse (mNOX-E36). mNOX-E36 is a murine-specific analogue of NOX-E36, an anti-MCP-1 L-RNA aptamer that was previously shown to attenuate liver fibrosis in mice [2] .
|
-
-
- HY-B0673S
-
|
AMR69-d5
|
TGF-beta/Smad
CCR
|
Inflammation/Immunology
Cancer
|
|
Pirfenidone-d5 (AMR69-d5) is a deuterium labeled Pirfenidone. Pirfenidone is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities [2] .
|
-
-
- HY-P99450
-
|
IPH 5401; Anti-C5aR1 mAb
|
Complement System
|
Inflammation/Immunology
Cancer
|
|
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
|
-
-
- HY-115644
-
|
|
Melanocortin Receptor
|
Inflammation/Immunology
|
|
BMS-470539 dihydrochloride is a highly potent and selective melanocortin-1 receptor (MC-1R) agonist with an IC50 of 120 nM, an EC50 of 28 nM. BMS-470539 dihydrochloride does not activate MC-3R and is a very weak partial agonist at MC-4R and MC-5R. BMS-470539 dihydrochloride has potently anti-inflammatory properties [2] .
|
-
-
- HY-120897
-
|
|
Bcl-2 Family
Apoptosis
|
Inflammation/Immunology
|
|
NS-3-008 hydrochloride is an orally active transcriptional inhibitor of G0/G1 switch 2 (G0s2) with an IC50 of 2.25 μM. NS-3-008 hydrochloride can be used for chronic kidney disease .
|
-
-
- HY-P991280
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
BMS-981164 is a human anti-IL31 IgG1-κ monoclonal antibody. BMS-981164 effectively inhibits the IL-31 signaling pathway. The isotype control of BMS-981164 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). BMS-981164 is applicable to research related to atopic dermatitis .
|
-
-
- HY-170415
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
EGR-1 IN-3 (Compound 36) is an early growth response 1 (EGR-1)-DNA binding disruptor. EGR-1-IN-3 inhibits TNFα-induced binding of EGR-1 to DNA and expression of genes associated with inflammation (such as TSLP, IL-31, IL-6 and CCL2). EGR-1-IN-3 can be used in the study of inflammatory diseases .
|
-
-
- HY-W013675
-
|
|
HSP
|
Inflammation/Immunology
|
|
2-Methoxyhydroquinone is a phenolic compound that reduces TNF-α-induced production of chemokine (C-C motif) ligand 2 (CCL2) with an IC50 value of 64.3 µM. 2-Methoxyhydroquinone is also a precursor in the synthesis of the Hsp90 inhibitor Geldanamycin (HY-15230) [2].
|
-
-
- HY-160552
-
|
|
Liposome
|
Others
|
|
244cis, a piperazine-containing ionizable cationic lipid, has been used to generate lipid nanoparticles (LNPs). LNPs containing 244cis and coated with mRNA reporter gene were specifically accumulated in mouse lungs compared with LNPs containing SM-102. Induces a decrease in serum chemokine (C-C motif) ligand 2 (CCL2) levels .
|
-
-
- HY-RS16514
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Ccl2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ccl2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Ccl2 Mouse Pre-designed siRNA Set A
Ccl2 Mouse Pre-designed siRNA Set A
-
- HY-116247
-
|
|
PPAR
|
Metabolic Disease
Inflammation/Immunology
|
|
ST247 a potent PPARβ/δ inverse agonist. ST247 has a higher affinity to PPARβ/δ. ST247 modulates expression of the activation marker CCL2 in the opposite direction. ST247 efficiently induces the interaction with corepressors. ST247 inhibits the agonist-induced transcriptional activity of PPARβ/δ .
|
-
-
- HY-148100A
-
|
NOX-E36 sodium
|
CCR
|
Cancer
|
|
Emapticap pegol sodium is a inhibitor of pro-inflammatory chemokine C-C motif-ligand 2 (CCL2). Emapticap pegol sodium is a 40-nucleotide oligonucleotide aptamer, displays different Spiegelmers (L-RNA aptamer) isform in human (NOX-E36) and mouse (mNOX-E36) [2] .
|
-
-
- HY-W007376R
-
|
3-Formylindole (Standard)
|
Reference Standards
Endogenous Metabolite
|
Others
|
|
Indole-3-carboxaldehyde (Standard) is the analytical standard of Indole-3-carboxaldehyde. This product is intended for research and analytical applications. Indole-3-carboxaldehyde (3-Formylindole), a banlangen extract, is the product of the oxidative degradation of indole-3-acetic acid (IAA) by crude enzyme preparations from etiolated pea seedlings. Indole-3-carboxaldehyde is a biochemical used to prepare analogs of the indole phytoalexin cyclobrassinin. Indole-3-carboxaldehyde also enhances the epithelial barrier and anti-inflammatory activity in the intestinal tract[1][2].
|
-
-
- HY-P99149
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TNFR2 Antibody (TR75-54.7) is an anti-mouse TNFR2 IgG monoclonal antibody. Anti-Mouse TNFR2 Antibody (TR75-54.7) can reduce white blood cell count (WBC) and decrease the expression of some pro-inflammatory cytokines such as CCL2 and CXCL5. Anti-Mouse TNFR2 Antibody (TR75-54.7) can be used for researches on inflammation conditions and cancer such as breast cancer [2].
|
-
-
- HY-149202
-
|
|
PGE synthase
|
Neurological Disease
Inflammation/Immunology
|
|
UT-11 is a potent and blood-brain barrier-permeable microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor with IC50s of 0.10 μM and 2.00 μM for inhibiting PGE2 production in human (SK-N-AS) and murine (BV2) cells, respectively .
|
-
-
- HY-P991208
-
|
human Flt3L; hFlt3L
|
FLT3
Interleukin Related
CCR
|
Inflammation/Immunology
|
|
Flt-3L-Ig (hum/hum) (hFlt3L) is a Flt3 ligand. Flt-3L-Ig (hum/hum) enhances the release of inflammatory cytokines from myeloid cells and dendritic cells in BRGSF-CBC mice induced by OKT3. Flt-3L-Ig (hum/hum) increases the release of IL-2, CCL2 and CXCL10 in an OKT3-dependent manner. Flt-3L-Ig (hum/hum) can be used in studies related to cytokine release syndrome. Flt-3L-Ig (hum/hum) can be used in studies related to psoriasis-like skin inflammation [2].
|
-
-
- HY-174763
-
|
|
mRNA
|
Inflammation/Immunology
|
|
Human CCL2 mRNA encodes the human C-C motif chemokine ligand 2 (CCL2) protein. CCL2 displays chemotactic activity for monocytes and basophils but not for neutrophils or eosinophils. It has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis and atherosclerosis.
|
-
-
- HY-121896
-
|
|
SHP2
|
Cancer
|
|
DSHN is a potent small heterodimer partner (SHP) activator. DSHN inhibits Ccl2 expression and secretion by inhibiting p65 activation of Ccl2 promoter activity. DSHN can be used in research of cancer .
|
-
-
- HY-RS02089
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
CCL2 Human Pre-designed siRNA Set A contains three designed siRNAs for CCL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
CCL2 Human Pre-designed siRNA Set A
CCL2 Human Pre-designed siRNA Set A
-
- HY-W104821
-
|
|
Keap1-Nrf2
|
Metabolic Disease
|
|
Rosolic Acid is an activator of Nrf2, as well as its downstream targets. Rosolic Acid increases the levels of angiogenic factors, decreases inflammation (TNF-α and IL-1β) and apoptotic markers (CXCL10 and CCL2). Rosolic Acid restores the function of pancreatic cells and protects endothelial cells (ECs) from endoplasmic reticulum stressed .
|
-
-
- HY-B1322R
-
|
Amodiaquin dihydrochloride dihydrate (Standard)
|
Nuclear Hormone Receptor 4A/NR4A
Reference Standards
Parasite
Histone Methyltransferase
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Amodiaquine (dihydrochloride dihydrate) (Standard) is the analytical standard of Amodiaquine (dihydrochloride dihydrate). This product is intended for research and analytical applications. Amodiaquine dihydrochloride dihydrate (Amodiaquin dihydrochloride dihydrate), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine dihydrochloride dihydrate is also a Nurr1 agonist and specifically binds to Nurr1-LBD (ligand binding domain) with an EC50 of ~20 μM. Anti-inflammatory effect [2] .
|
-
-
- HY-176255
-
|
|
Molecular Glues
Interleukin Related
CCR
|
Inflammation/Immunology
|
|
TBK1 degrader-4 (Compound 30) is a molecular glue degrader targeting TBK1. TBK1 degrader-4 effectively inhibits cyst growth, alleviates inflammation, and reduces the levels of pro-inflammatory factors such as Ccl2, IFNβ, and IL-6. TBK1 degrader-4 is promising for research of autosomal dominant polycystic kidney disease (ADPKD) .
|
-
-
- HY-178926
-
|
|
CCR
TNF Receptor
Interleukin Related
|
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
|
RAGE406R is an orally active RAGE-DIAPH1 interaction antagonist. RAGE406R can bind to ctRAGE and prevent the formation of the RAGE-DIAPH1 complex and inhibit its interaction. RAGE406R can reduce the expression of CCL2, TNF, and IL-6 in THP1 cells. RAGE406R suppresses delayed-type hypersensitivity in T2D mice. RAGE406R can be used for the study of diabetes .
|
-
-
- HY-RS22945
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Ccl2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ccl2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Ccl2 Rat Pre-designed siRNA Set A
Ccl2 Rat Pre-designed siRNA Set A
-
- HY-P11553
-
|
|
CCR
|
Inflammation/Immunology
|
|
ECL1i is an allosteric, selective CCR2 inhibitor. ECL1i specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .
|
-
-
- HY-P11553A
-
|
|
CCR
|
Infection
Inflammation/Immunology
|
|
ECL1i TFA is an allosteric, selective CCR2 inhibitor. ECL1i TFA specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i TFA interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .
|
-
-
- HY-171683
-
|
|
Antibody-Drug Conjugates (ADCs)
CCR
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Anti-CCL2 (Carlumab)-VcMMAE is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with valine-citrulline (vc) and the tubulin inhibitor MMAE (HY-15162). The ADC toxic molecule and linker part are McMMAE (HY-15575). Anti-CCL2 (Carlumab)-VcMMAE induces apoptosis and can be used in cancer research [2].
|
-
-
- HY-171682
-
|
|
Antibody-Drug Conjugates (ADCs)
CCR
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Anti-CCL2 (Carlumab)-McMMAF is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated to the protective group maleimidocaproyl and the tubulin inhibitor MMAF (HY-15579). The ADC toxic molecule and linker part are McMMAF (HY-15578). Anti-CCL2 (Carlumab)-McMMAF induces apoptosis and can be used in cancer research [2].
|
-
-
- HY-165528
-
|
XC8
|
CCR
|
Inflammation/Immunology
|
|
Histamine glutarimide (XC8) is an orally active anti-asthma agent. Histamine glutarimide blocks the maturation of chemokines (CCL2, CCL7, CCL8, CCL13) and inhibits the migration of eosinophils and the degranulation of mast cells. In asthma models induced by carrageenan and rat ovalbumin, Histamine glutarimide can reduce airway resistance and the count of eosinophils in bronchoalveolar lavage fluid. Histamine glutarimide can be used in asthma research .
|
-
-
- HY-171681
-
|
|
Antibody-Drug Conjugates (ADCs)
CCR
Microtubule/Tubulin
|
Cancer
|
|
Anti-CCL2 (Carlumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with the linker SPDB (HY-12448) and the tubulin inhibitor DM4 (HY-12454). The ADC toxic molecule and linker part are sulfo-SPDB-DM4 (HY-101141). Anti-CCL2 (Carlumab)-SPDB-DM4 can be used in cancer research [2].
|
-
-
- HY-171680
-
|
|
Antibody-Drug Conjugates (ADCs)
CCR
Microtubule/Tubulin
|
Cancer
|
|
Anti-CCL2 (Carlumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated to the linker SMCC (HY-42360) and the cytotoxic microtubule inhibitor DM1 (HY-19792). The ADC toxic molecule and linker part are SMCC-DM1 (HY-101070). Anti-CCL2 (Carlumab)-SMCC-DM1 can be used in the research of cancer, especially prostate cancer [2].
|
-
-
- HY-N3887
-
|
Haplophytin B; Haplophytine B
|
Bacterial
|
Infection
|
|
Evoxine (Haplophytin B) is a compound that selectively inhibits CO2-induced immunosuppression and has activity in inhibiting the expression of interleukin-6 and chemokine CCL2 in human THP-1 macrophages. Evoxine shows antimicrobial activity against a wide range of bacteria, especially performing well in minimum inhibitory concentration (MIC) tests against Escherichia coli, Bacillus subtilis, and Staphylococcus aureus. Evoxine extracts may find application in crude drug preparations in West Africa, provided that their in vivo toxicity results are negative .
|
-
-
- HY-171684
-
|
|
Antibody-Drug Conjugates (ADCs)
CCR
Topoisomerase
|
Cancer
|
|
Anti-CCL2 (Carlumab)-MC-Vc-PAB-SN38 is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated to the linker Mc-VC-PAB and the topoisomerase I inhibitor SN38 (HY-13704). The ADC toxic molecule and linker part are Mc-VC-PAB-SN38 (HY-131057). Anti-CCL2 (Carlumab)-MC-Vc-PAB-SN38 can be used in cancer research [2].
|
-
-
- HY-171685
-
-
-
- HY-108554
-
|
|
Protease Activated Receptor (PAR)
|
Others
|
|
Q94 hydrochloride, a selective PAR1 antagonist (IC50=916 nM), can selectively block PAR1/Gαq interaction and signalling. Q94 hydrochloride blocks PAR1-mediated increases in both CCL2 mRNA and protein levels in a dose-dependent manner. Q94 hydrochloride also completely blocks thrombin-induced ERK1/2 and MLC phosphorylation .
|
-
- HY-B1322AR
-
-
- HY-168782
-
|
|
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
|
|
Resolvin D2 n-3 DPA is a specialized proresolving mediator (SPM). Resolvin D2 n-3 DPA (1 nM) can reduce the chemotaxis and adhesion of human neutrophils induced by TNF-α. Resolvin D2 n-3 DPA (100 ng/mouse; intravenous injection) can reduce neutrophil infiltration in the peritoneum and the levels of IL-6 and the chemokine (C-C motif) ligand 2 (CCL2) in a mouse model of inflammation induced by zinc oxide .
|
-
- HY-B1076R
-
|
HMS (Standard); 6α-Methyl-11β-hydroxyprogesterone (Standard)
|
Reference Standards
STAT
VEGFR
CCR
|
Inflammation/Immunology
|
|
Medrysone (Standard) is the analytical standard of Medrysone. This product is intended for research and analytical applications. Medrysone (HMS; 6α-Methyl-11β-hydroxyprogesterone) is a STAT6 modulator and M2 macrophage polarization inducer. Medrysone enhances IL-4-triggered STAT6 activation, upregulates the expression of M2 markers, and promotes the secretion of VEGF and CCL2. Medrysone also enhances the pro-migratory activity of M2-like macrophages toward endothelial cells. By regulating macrophage polarization and related repair pathways, Medrysone significantly promotes corneal wound repair in a rat mechanical injury model. Medrysone can be used for research related to corneal injury [2].
|
-
- HY-171895
-
|
12-Nitro-9-cis,12-cis-octadecadienoic acid
|
PPAR
Interleukin Related
NF-κB
TNF Receptor
|
Inflammation/Immunology
|
|
12-Nitrolinoleate (12-Nitro-9-cis,12-cis-octadecadienoic acid) is an activator for peroxisome proliferator-activated receptor γ (PPARγ). 12-Nitrolinoleate is a nitrated form of linoleic acid. 12-Nitrolinoleate can be formed upon exposure to acidified nitrate and found in human red blood cells and plasma. 12-Nitrolinoleate can activate PPARγ-dependent gene expression in MCF-7 cells expressing PPARγ with an EC50 = 0.045 μM. 12-Nitrolinoleate is able to inhibit LPS (HY-D1056)-induced NF-κB transcription in RAW 264.7 cells. 12-Nitrolinoleate can inhibit IL-6, TNF-α and CCL2 induced by LPS [2] .
|
-
- HY-173518
-
|
|
Heme Oxygenase (HO)
Reactive Oxygen Species (ROS)
NO Synthase
COX
Interleukin Related
|
Inflammation/Immunology
|
|
SIN 14, a derivative of Sinomenine (HY-15122), is an orally active HO-1 activator (KD = 17.2 μM). SIN 14 binds to the catalytic core domain of HO-1 and induces HO-1 activation in catalysis. SIN 14 significantly increases HO-1 stability. SIN 14 has anti-inflammatory effects and inhibits M1 macrophage polarization while promoting M2 polarization in LPS (Lipopolysaccharides)(HY-D1056)-induced RAW264.7 cells. SIN 14 inhibits inflammatory mediator production (eg: NO, IL-6, IL-1β and CCL2, inhibits production of ROS and down-regulates the expression of COX-2 and iNOS. SIN 14 can inhibit RA-related inflammatory edema in collagen-induced arthritis (ClA) mice .
|
-
- HY-B1203S
-
|
9α-Fludrocortisone-d5; 9α-Fluorcortisol-d5
|
Isotope-Labeled Compounds
Mineralocorticoid Receptor
Glucocorticoid Receptor
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Fludrocortisone-d5 (9α-Fludrocortisone-d5) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.
|
-
- HY-B1203R
-
|
9α-Fludrocortisone (Standard); 9α-Fluorcortisol (Standard)
|
Reference Standards
Mineralocorticoid Receptor
Glucocorticoid Receptor
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Fludrocortisone (Standard) (9α-Fludrocortisone (Standard)) is the analytical standard of Fludrocortisone (HY-B1203). This product is intended for research and analytical applications. Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.
|
-
- HY-B1203S1
-
|
9α-Fludrocortisone-d2; 9α-Fluorcortisol-d2
|
Isotope-Labeled Compounds
Mineralocorticoid Receptor
Glucocorticoid Receptor
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Fludrocortisone-d2 (9α-Fludrocortisone-d2) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.
|
-
- HY-180831
-
|
|
Epigenetic Reader Domain
|
Metabolic Disease
Inflammation/Immunology
|
|
BRD4 D1-IN-3 (compound 39) is a potent, selective, and cell-active BRD4-D1 inhibitor (IC50 = 39 nM, Ki = 2.4 nM) with >1700-fold selectivity over BRD2-D1. BRD4 D1-IN-3 reduces the expression of pro-inflammatory chemokines CXCL1 and CCL2 in an LPS (HY-D1056)-mediated cellular model of liver inflammation. BRD4 D1-IN-3 can be used for liver inflammation research .
|
-
- HY-177933
-
|
|
CCR
|
Neurological Disease
Inflammation/Immunology
|
|
mNOX-E36 is a murine-specific analogue of NOX-E36 (HY-148100), an anti-CCL-2 L-RNA aptamer that binds and neutralises the mouse chemokine CCL-2. mNOX-E36 reduces scarring in an experimental murine model of glaucoma filtration surgery (GFS). mNOX-E36 ameliorates lupus nephritis in mice. mNOX-E36 can be used for GFS and lupus nephritis research [2].
|
-
- HY-163655
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Glutaminyl Cyclase Inhibitor 6 (compound BI-43) is a secretory glutaminyl cyclase (sQC) and golgi-resident glutaminyl cyclase (gQC) inhibitor with IC50 values of 0.012 0.040 µM, respectively. Glutaminyl Cyclase Inhibitor 6 has the potential for the research of Parkinson’s disease .
|
-
- HY-B1322AS1
-
-
- HY-B1322BR
-
|
Amodiaquin dihydrochloride (Standard)
|
Nuclear Hormone Receptor 4A/NR4A
Parasite
Histone Methyltransferase
Reference Standards
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Amodiaquine (dihydrochloride) (Standard) is the analytical standard of Amodiaquine (dihydrochloride). This product is intended for research and analytical applications. Amodiaquine dihydrochloride (Amodiaquin dihydrochloride), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor with a Ki of 18.6 nM. Amodiaquine dihydrochloride is also a Nurr1 agonist and specifically binds to Nurr1-LBD (ligand binding domain) with an EC50 of ~20 μM. Anti-inflammatory effect [2] .
|
-
- HY-185153
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MC-VC-PAB-DMEA-PEG2-Duocarmycin SA is a drug-linker conjugate for ADC. MC-VC-PAB-DMEA-PEG2-Duocarmycin SA can be coupled with Carlumab (HY-P99188) to form Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA (HY-171685).
|
-
- HY-144334
-
|
|
CHIKV
DNA/RNA Synthesis
|
Infection
|
|
CHIKV-IN-3 is a potent against two low-passage CHIKV inhibitor with EC50 values of 1.55 and 0.14 μM for CHIKV-122508 and CHIKV-6708, respectively. CHIKV-IN-3 acts on the host cells to interfere with the viral replication. CHIKV-IN-3 displays minimal cytotoxic liability (CC50>100 μM). Prophylactic effect .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-W104821
-
|
|
Biochemical Assay Reagents
|
|
Rosolic Acid is an activator of Nrf2, as well as its downstream targets. Rosolic Acid increases the levels of angiogenic factors, decreases inflammation (TNF-α and IL-1β) and apoptotic markers (CXCL10 and CCL2). Rosolic Acid restores the function of pancreatic cells and protects endothelial cells (ECs) from endoplasmic reticulum stressed .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P11553
-
|
|
CCR
|
Inflammation/Immunology
|
|
ECL1i is an allosteric, selective CCR2 inhibitor. ECL1i specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .
|
-
- HY-P11553A
-
|
|
CCR
|
Infection
Inflammation/Immunology
|
|
ECL1i TFA is an allosteric, selective CCR2 inhibitor. ECL1i TFA specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i TFA interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .
|
-
- HY-144334
-
|
|
CHIKV
DNA/RNA Synthesis
|
Infection
|
|
CHIKV-IN-3 is a potent against two low-passage CHIKV inhibitor with EC50 values of 1.55 and 0.14 μM for CHIKV-122508 and CHIKV-6708, respectively. CHIKV-IN-3 acts on the host cells to interfere with the viral replication. CHIKV-IN-3 displays minimal cytotoxic liability (CC50>100 μM). Prophylactic effect .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P99188
-
|
CNTO 888
|
CCR
|
Cancer
|
|
Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) monoclonal antibody. Carlumab binds and neutralises profibrotic activities of human CCL2. Carlumab inhibits tumor growth by reducing macrophage infiltration and decreasing tumor microvascular density. Carlumab can be used for the research of cancer, suah as prostate cancer [2].
|
-
(5)
-
- HY-P990297
-
|
|
CCR
HIV
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV [2] .
|
-
(5)
-
- HY-P99781
-
|
MLN-1202
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) [2] .
|
-
(5)
-
- HY-P99450
-
|
IPH 5401; Anti-C5aR1 mAb
|
Complement System
|
Inflammation/Immunology
Cancer
|
|
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
|
-
(5)
-
- HY-P991280
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
BMS-981164 is a human anti-IL31 IgG1-κ monoclonal antibody. BMS-981164 effectively inhibits the IL-31 signaling pathway. The isotype control of BMS-981164 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). BMS-981164 is applicable to research related to atopic dermatitis .
|
-
(5)
-
- HY-P99149
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TNFR2 Antibody (TR75-54.7) is an anti-mouse TNFR2 IgG monoclonal antibody. Anti-Mouse TNFR2 Antibody (TR75-54.7) can reduce white blood cell count (WBC) and decrease the expression of some pro-inflammatory cytokines such as CCL2 and CXCL5. Anti-Mouse TNFR2 Antibody (TR75-54.7) can be used for researches on inflammation conditions and cancer such as breast cancer [2].
|
-
(5)
-
- HY-P991208
-
|
human Flt3L; hFlt3L
|
FLT3
Interleukin Related
CCR
|
Inflammation/Immunology
|
|
Flt-3L-Ig (hum/hum) (hFlt3L) is a Flt3 ligand. Flt-3L-Ig (hum/hum) enhances the release of inflammatory cytokines from myeloid cells and dendritic cells in BRGSF-CBC mice induced by OKT3. Flt-3L-Ig (hum/hum) increases the release of IL-2, CCL2 and CXCL10 in an OKT3-dependent manner. Flt-3L-Ig (hum/hum) can be used in studies related to cytokine release syndrome. Flt-3L-Ig (hum/hum) can be used in studies related to psoriasis-like skin inflammation [2].
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-W007376
-
-
-
- HY-B0498
-
-
-
- HY-N0444
-
|
|
Quinones
Structural Classification
Classification of Application Fields
Anthraquinones
Rubiaceae
Phenols
Polyphenols
Plants
Morinda officinalis How
Inflammation/Immunology
Disease Research Fields
Source Classification
|
Reactive Oxygen Species (ROS)
|
|
Rubiadin is an orally active polyketide-derived compound and free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections [2] .
|
-
-
- HY-W007376R
-
-
-
- HY-N3887
-
|
Haplophytin B; Haplophytine B
|
Alkaloids
Other Alkaloids
Rutaceae
Plants
Haplophyllum acutifolium (DC.) G. Don
Source Classification
|
Bacterial
|
|
Evoxine (Haplophytin B) is a compound that selectively inhibits CO2-induced immunosuppression and has activity in inhibiting the expression of interleukin-6 and chemokine CCL2 in human THP-1 macrophages. Evoxine shows antimicrobial activity against a wide range of bacteria, especially performing well in minimum inhibitory concentration (MIC) tests against Escherichia coli, Bacillus subtilis, and Staphylococcus aureus. Evoxine extracts may find application in crude drug preparations in West Africa, provided that their in vivo toxicity results are negative .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0673S1
-
|
|
|
Deupirfenidone-d3 is the deuterium labeled Pirfenidone (HY-B0673). Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities [2] .
|
-
-
- HY-B0673S
-
|
|
|
Pirfenidone-d5 (AMR69-d5) is a deuterium labeled Pirfenidone. Pirfenidone is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities [2] .
|
-
-
- HY-B1203S
-
|
|
|
Fludrocortisone-d5 (9α-Fludrocortisone-d5) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.
|
-
-
- HY-B1203S1
-
|
|
|
Fludrocortisone-d2 (9α-Fludrocortisone-d2) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.
|
-
-
- HY-B1322AS1
-
|
|
|
Amodiaquine-d10 hydrochloride is deuterated labeled Amodiaquine (HY-B1322A). Amodiaquine (Amodiaquin), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine is also a Nurr1 agonist and specifically binds to Nurr1-LBD (ligand binding domain) with an EC50 of ~20 μM. Anti-inflammatory effect [2] .
|
-
| Cat. No. |
Compare |
Product Name |
Application |
Reactivity |
Image |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Host |
|
| Reactivity |
|
| Application |
|
Dilution Ratio |
|
| Molecular Weight |
|
| Conjugation |
|
| Clonality |
|
| Immunogen |
|
| Appearance |
|
| Isotype |
|
| Gene ID |
|
| SwissProt ID |
|
| Purity |
|
| Formulation |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-148100
-
|
NOX-E36
|
|
Aptamers
|
|
Emapticap pegol (NOX-E36) is a inhibitor of pro-inflammatory chemokine C-C motif-ligand 2 (CCL2). Emapticap pegol is a 40-nucleotide oligonucleotide aptamer, displays different Spiegelmers (L-RNA aptamer) isform in human (NOX-E36) and mouse (mNOX-E36). mNOX-E36 is a murine-specific analogue of NOX-E36, an anti-MCP-1 L-RNA aptamer that was previously shown to attenuate liver fibrosis in mice [2] .
|
-
- HY-160552
-
|
|
|
Cationic Lipids
|
|
244cis, a piperazine-containing ionizable cationic lipid, has been used to generate lipid nanoparticles (LNPs). LNPs containing 244cis and coated with mRNA reporter gene were specifically accumulated in mouse lungs compared with LNPs containing SM-102. Induces a decrease in serum chemokine (C-C motif) ligand 2 (CCL2) levels .
|
-
- HY-RS16514
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Ccl2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ccl2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-148100A
-
|
NOX-E36 sodium
|
|
Aptamers
|
|
Emapticap pegol sodium is a inhibitor of pro-inflammatory chemokine C-C motif-ligand 2 (CCL2). Emapticap pegol sodium is a 40-nucleotide oligonucleotide aptamer, displays different Spiegelmers (L-RNA aptamer) isform in human (NOX-E36) and mouse (mNOX-E36) [2] .
|
-
- HY-174763
-
|
|
|
mRNA
Chemokine & Receptors
|
|
Human CCL2 mRNA encodes the human C-C motif chemokine ligand 2 (CCL2) protein. CCL2 displays chemotactic activity for monocytes and basophils but not for neutrophils or eosinophils. It has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis and atherosclerosis.
|
-
- HY-RS02089
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
CCL2 Human Pre-designed siRNA Set A contains three designed siRNAs for CCL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS22945
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Ccl2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ccl2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-177933
-
|
|
|
Aptamers
|
|
mNOX-E36 is a murine-specific analogue of NOX-E36 (HY-148100), an anti-CCL-2 L-RNA aptamer that binds and neutralises the mouse chemokine CCL-2. mNOX-E36 reduces scarring in an experimental murine model of glaucoma filtration surgery (GFS). mNOX-E36 ameliorates lupus nephritis in mice. mNOX-E36 can be used for GFS and lupus nephritis research [2].
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: